Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

被引：16

作者：

Yamamoto, Takafumi ^{[1
]}

Ito, Takanori ^{[1
]}

Hase, Tetsunari ^{[2
]}

Ishigami, Masatoshi ^{[1
]}

Mizuno, Kazuyuki ^{[1
]}

Yamamoto, Kenta ^{[1
]}

Imai, Norihiro ^{[1
]}

Ishizu, Yoji ^{[1
]}

Honda, Takashi ^{[1
]}

Shibata, Hirofumi ^{[2
]}

Hatta, Takahiro ^{[2
]}

Yogo, Naoyuki ^{[2
]}

Yasuda, Satoshi ^{[3
]}

Toyoda, Hidenori ^{[3
]}

Abe, Takashi ^{[4
]}

Kawashima, Hiroki ^{[5
]}

Hashimoto, Naozumi ^{[2
]}

Fujishiro, Mitsuhiro ^{[1
]}

机构：

[1] Nagoya Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Nagoya, Aichi, Japan

[2] Nagoya Univ, Dept Resp Med, Grad Sch Med, Nagoya, Aichi, Japan

[3] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Japan

[4] Ogaki Municipal Hosp, Dept Resp Med, Ogaki, Japan

[5] Nagoya Univ Hosp, Dept Endoscopy, Nagoya, Aichi, Japan

来源：

CANCER INVESTIGATION | 2022年 / 40卷 / 02期

关键词：

Nonsmall cell lung cancer; immune checkpoint inhibitor; immune-related adverse events; liver injury; prognosis; ADVERSE EVENTS; NIVOLUMAB; ASSOCIATION; DOCETAXEL; VITILIGO; EFFICACY;

D O I：

10.1080/07357907.2021.1994586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in nonsmall cell lung carcinoma (NSCLC) patients. Of the 365 NSCLC patients treated with immune checkpoint inhibitors (ICIs), 19 suffered from severe liver-irAEs (grade >= 3). The median time-to-onset of liver-irAEs was 53 days postinjection of the first ICI. The progression-free survival and overall survival of the liver-irAEs group (median 69 and 262 days, respectively) were significantly worse than the nonliver-irAEs group (128 and 722 days; P = 0.010 and P = 0.007; respectively). In conclusion, liver-irAEs were associated with poor prognosis in NSCLC patients.

引用

页码：189 / 198

页数：10

共 33 条

[1] Case Definition and Phenotype Standardization in Drug-Induced Liver Injury [J].

Aithal, G. P. ;

Watkins, P. B. ;

Andrade, R. J. ;

Larrey, D. ;

Molokhia, M. ;

Takikawa, H. ;

Hunt, C. M. ;

Wilke, R. A. ;

Avigan, M. ;

Kaplowitz, N. ;

Bjornsson, E. ;

Daly, A. K. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (06) :806-815

[2] Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer [J].

Ali, Omar Hasan ;

Diem, Stefan ;

Markert, Eva ;

Jochum, Wolfram ;

Kerl, Katrin ;

French, Lars E. ;

Speiser, Daniel E. ;

Fruh, Martin ;

Flatz, Lukas .

OncoImmunology, 2016, 5 (11)

[3] EASL Clinical Practice Guidelines: Drug-induced liver injury [J].

Andrade, Raul J. ;

Aithal, Guruprasad P. ;

Bjornsson, Einar S. ;

Kaplowitz, Neil ;

Kullak-Ublick, Gerd A. ;

Karlsen, Tom H. .

JOURNAL OF HEPATOLOGY, 2019, 70 (06) :1222-1261

[4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination [J].

Boutros, Celine ;

Tarhini, Ahmad ;

Routier, Emilie ;

Lambotte, Olivier ;

Ladurie, Francois Leroy ;

Carbonnel, Franck ;

Izzeddine, Hassane ;

Marabelle, Aurelien ;

Champiat, Stephane ;

Berdelou, Armandine ;

Lanoy, Emilie ;

Texier, Matthieu ;

Libenciuc, Cristina ;

Eggermont, Alexander M. M. ;

Soria, Jean-Charles ;

Mateus, Christine ;

Robert, Caroline .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) :473-486

[6] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[7] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[8] Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade [J].

Downey, Stephanie G. ;

Klapper, Jacob A. ;

Smith, Franz O. ;

Yang, James C. ;

Sherry, Richard M. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Hughes, Marybeth S. ;

Allen, Tamika E. ;

Levy, Catherine L. ;

Yellin, Michael ;

Nich, Geoffrey ;

White, Donald E. ;

Steinberg, Seth M. ;

Rosenberg, Steven A. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6681-6688

[9] Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes [J].

Freeman-Keller, Morganna ;

Kim, Youngchul ;

Cronin, Heather ;

Richards, Allison ;

Gibney, Geoffrey ;

Weber, Jeffrey S. .

CLINICAL CANCER RESEARCH, 2016, 22 (04) :886-894

[10] Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors [J].

Fukihara, Jun ;

Sakamoto, Koji ;

Koyama, Junji ;

Ito, Takayasu ;

Iwano, Shingo ;

Morise, Masahiro ;

Ogawa, Masahiro ;

Kondoh, Yasuhiro ;

Kimura, Tomoki ;

Hashimoto, Naozumi ;

Hasegawa, Yoshinori .

CLINICAL LUNG CANCER, 2019, 20 (06) :442-+

← 1 2 3 4 →